Time to steroids impacts visual outcome of optic neuritis in MOGAD

Background To characterise the response to treatment of inaugural optic neuritis (ON) in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Methods We searched the French MOGAD database for adults with inaugural ON with a detailed report of acute treatment modalities and measures of high-contrast best-corrected visual acuity (BCVA) at nadir and after 3 months. Predictors of visual outcomes were assessed by multivariable analysis. Results Among 245 patients with at least one episode of ON, 82 fulfilled all criteria, and data on the peripapillary retinal nerve fibre layer (pRNFL) were available for 44. All patients received methylprednisolone (MP), combined with plasma exchange in 18. After 3 months, 75 of 82 (91%) patients retained full BCVA recovery, and median (range) pRNFL of the affected eye was 72 µm (40–102). Failure to regain 0.0 logarithmic minimum angle of resolution vision (Snellen 20/20) at 3 months was associated with time to first MP treatment ≥10 days (OR 16, 95% CI 1.14 to 213, p=0.01). pRNFL thickness after 3 months was related to better BCVA at nadir and time to first MP treatment <10 days (r2=19%, p=0.004 and r2=11%, p=0.03, respectively). Conclusions Time to MP affects functional but also structural visual outcomes of ON in MOGAD.

[1]  G. Wollstein,et al.  Normative Data and Conversion Equation for Spectral-Domain Optical Coherence Tomography in an International Healthy Control Cohort , 2022, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[2]  S. Saidha,et al.  Longitudinal Retinal Changes in MOGAD , 2022, Annals of neurology.

[3]  T. Nakazawa,et al.  Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD , 2022, Journal of the Neurological Sciences.

[4]  S. Vukusic,et al.  Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study , 2022, Journal of neuroinflammation.

[5]  Jacqueline Palace,et al.  Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease in the United Kingdom , 2022, JAMA network open.

[6]  S. Saidha,et al.  OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS. , 2022, Multiple sclerosis and related disorders.

[7]  J. Palace,et al.  The use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis , 2021, Multiple sclerosis journal - experimental, translational and clinical.

[8]  A. Klistorner,et al.  Structural and functional markers of optic nerve damage in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis , 2021, Multiple sclerosis journal - experimental, translational and clinical.

[9]  O. Ciccarelli,et al.  Myelin-oligodendrocyte glycoprotein antibody-associated disease , 2021, The Lancet Neurology.

[10]  T. Nakazawa,et al.  Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease. , 2021, Multiple sclerosis and related disorders.

[11]  M. Krumbholz,et al.  Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well? , 2021, Journal of neuroinflammation.

[12]  J. Schuman,et al.  APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies , 2021, Neurology.

[13]  Jerry L Prince,et al.  Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning , 2020, Multiple sclerosis.

[14]  A. Lecler,et al.  Visual field loss and structure–function relationships in optic neuritis associated with myelin oligodendrocyte glycoprotein antibody , 2020, Multiple sclerosis.

[15]  M. Bach,et al.  Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[16]  B. Weinshenker,et al.  Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. , 2018, American journal of ophthalmology.

[17]  P. Lebranchu,et al.  Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults , 2018, Neurology.

[18]  V. Fung,et al.  Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[19]  P. Cabre,et al.  Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[20]  F. Paul,et al.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients , 2016, Journal of Neuroinflammation.

[21]  M. Sepúlveda,et al.  Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications , 2016, Multiple sclerosis.

[22]  B. Banwell,et al.  Functional–structural correlations in the afferent visual pathway in pediatric demyelination , 2014, Neurology.

[23]  T. Nakazawa,et al.  Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.